Vericel Corporation (VCEL)
Vericel Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Burlington, MA, US. The stock last traded at $39.60, up 3.29% on the session, giving a market capitalisation of $2.03B. On trailing twelve-month figures it carries a trailing P/E of 82.50, a net margin of 7.9%. Its beta of 1.05 implies it has historically moved more than the broad market.
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Vericel Corporation is most often compared with the following Healthcare names: